跳至主要内容
临床试验/NCT02691351
NCT02691351已完成不适用

Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study

Samsung Medical Center1 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2016年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
500
试验地点
1
主要终点
Overall survival

研究概览

简要总结

The better understanding of non-Hodgkin T-cell lymphoma is essential for establishing effective treatment strategy for non-Hodgkin T-cell lymphoma. Therefore, the data about conical features and treatment outcomes of each subtype should be accumulated to establish treatment strategy. However, the majority of previous data for non-Hodgkin T-cell lymphoma was from small case series of single institute. Furthermore, as novel drugs were developed for the treatment of relapsed or refractory T-cell lymphoma, the date from patients who were treated with those novel drugs are especially required because their outcomes may reflect the outcomes of currently available treatments. Thus, a multinational, multicenter prospective registry study is needed to provide information useful for establishing treatment strategies for T-cell lymphoma.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Pathologically diagnosed Mature T-cell non-Hodgkin lymphoma based on the World Health Organization classification 2008
  • Newly diagnosed patients without a previous treatment history for T-cell lymphoma or relapsed/refractory T-cell lymphoma patients
  • Age ≥19 years
  • Written informed consent

排除标准

  • Hodgkin lymphoma
  • non-Hodgkin B-cell lymphoma
  • Immature non-Hodgkin T-cell lymphoma: Precursor T-lymphoblastic lymphoma/leukemia
  • Not understanding informed consent

结局指标

主要结局

Overall survival

时间窗: 5 years

次要结局

  • Overall response rate to primary treatment and salvage treatment(5 years)
  • Progression-free survival(5 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Won Seog Kim

Principal Investigator

Samsung Medical Center

研究点 (1)

Loading locations...

相似试验